Lupus Initiative

Lupus, or Systemic Lupus Erythematosus (SLE), is a chronic autoimmune disease in which the body’s immune system mistakenly attacks its own healthy tissues and organs.

Phase I
Systems Architecture
Systems Architecture
Status: In Progress
The Systems Architecture of Lupus is published as a web based tool open to public.
Phase II
Publications
Publications
Status: Open
A peer-reviewed paper from the Lupus Initiative will be published in the Journal for benefit of the community.
Phase III
In Silico Modeling
In Silico Modeling
Status: Open
In this phase, in silico modeling will develop mathematical models of Lupus pathogenesis. This phase is in progress.
Phase IV
Combination Screening
Combination Screening
Status: Open
Combination Screening will be conducted to identify compounds targeting biological processes in Lupus pathogenesis.
Phase V
Patents
Patents
Status: Open
In this phase, a US patent will be filed for the newly discovered combination(s).
Phase VI
Licensing and Manufacturing
Licensing and Manufacturing
Status: Open
The Lupus health Initiative will license and manufacture nutraceuticals to support treatment of Lupus.

Background on Lupus

Lupus, or systemic lupus erythematosus (SLE), is a chronic autoimmune disease in which the body’s immune system mistakenly attacks its own healthy tissues and organs. This can lead to inflammation and damage affecting various parts of the body, including the skin, joints, kidneys, brain, heart, and lungs. Because it can affect so many different systems, lupus is often called “the great imitator.” The exact cause of lupus is unknown, but it’s believed to involve a combination of genetic, hormonal, and environmental factors. It’s more common in women, particularly during their childbearing years, and certain ethnic groups are also more susceptible. Lupus is characterized by periods of illness, called flares, where symptoms worsen, alternating with times of remission when symptoms improve or disappear. Symptoms can vary widely from person to person and can change over time. Some common symptoms include extreme fatigue, joint pain and swelling, skin rashes (the butterfly-shaped rash across the cheeks and nose is a classic sign), fever, hair loss, and sensitivity to sunlight. Diagnosing lupus can be challenging due to its diverse symptoms and the fact that there’s no single definitive test. Doctors typically rely on a combination of medical history, physical examination, blood tests (like the antinuclear antibody or ANA test), and urine tests. While there’s no cure for lupus, the goal of treatment is to manage symptoms, reduce inflammation, prevent organ damage, and minimize flares. Treatment plans are highly individualized and may involve medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antimalarial drugs, immunosuppressants, and biologics. With proper management and ongoing medical care, many people with lupus can lead fulfilling lives

Systems Architecture

The Systems Architecture of Lupus is published as a web based tool open to public . Click below to interact with the Systems Architecture. This phase is still in progress.

Publication

A peer-reviewed paper from the Lupus Initiative will be published in the Journal for benefit of the community. This phase is yet to begin.

In Silico Modeling

In this phase, the Lupus initiative will conduct in silico modeling to identify and test the efficacy of natural compounds against the Lupus diseases. This phase is yet to begin.

Combination Screening

In this phase, combination screening will be performed to identify potential ingredient/compounds that target the biological process implicated in Lupus pathogenesis. This phase is yet to begin

Patents

The Open Science Institute® through its Lupus Initiative is moving towards getting patents for a revolutionary molecule that effectively combats Lupus disease, contributing breakthrough real solutions to society worldwide.

Licensing and Manufacturing

The Lupus Initiative plans to discover, develop, license and manufacture proprietary nutraceuticals to support treatment of Lupus. Support our mission to bring this innovation to those who need it most. Please support this phase by donating to the Lupus Initiative

Health-product-label-09-10-2025